Asp–Tyr–Leu–Lys tetrapeptide inhibits airway inflammation in toluene‐2,4‐diisocyanate‐induced asthma mice

Abstract

Local administration of DYLK effectively inhibits the airway inflammation and airway remodelling of TDI-sensitized/challenged mice via down-regulation of VEGF. These findings suggest that anti-angiogenic peptide therapies, such as local administration of DYLK, are an effective strategy for the treatment of remodelling in asthma.